Bank 51 batch3 telegram 8 c

Industries / Pharma and medical distribution

Pharma and medical distribution. Cash: stock bought early to earn supplier rebates.

Grip reads prescriptions, supplier terms and stock records, branch by branch, and names the margin lost to price and timing and the cash held in stock, in AED.

Discuss your business →See it run ↓
USD 64.9 millionFall in one US infusion pharmacy group's operating cash in 2025, mainly from stock bought early for supplier rebates.
Proven at Option Care Health

Source: Option Care Health, Inc., Form 10-K for fiscal year 2025 (filed 24 February 2026). Option Care Health's operating cash flow fell to $258,447 thousand in 2025 from $323,392 thousand, mainly because it built inventory through strategic purchases to maximise volume rebates and prompt-pay discounts and because receivables grew with revenue; buying for the rebate shows up as cost savings in margin but as cash tied up on the shelf.

3 workflows

Where we start.

9 of 24 changes other pharma and medical distribution companies made. Open one to see the company.

01

Price and margin

Price, volume and launches split apart, prescription profit read by payer.

ReadsSales by product with price and volumePrice list and tender historySales by product and brand per branchProduct margins, planograms
Each year, split revenue change into falling prices, volume and new launches, to see drops.
Proven at Hikma Pharmaceuticals

Source: Hikma Pharmaceuticals PLC, Annual Report 2025, Strategic report.

Measure own-brand sales as a share of the till, and grow it where low.
Proven at CVS Health

Source: CVS Health Corporation, Form 10-K for fiscal year ended 31 December 2025.

Work out profit on each prescription by payer, and fix the ones that lose money.
Proven at Walgreens Boots Alliance

Source: Walgreens Boots Alliance, Inc., Form 10-K for fiscal year ended 31 August 2024.

02

Cash and working capital

Stock held against orders, forward buying weighed against cash tied up.

ReadsInventory by product and stageSales orders and tender awards, production planPurchase ledger by vendor with rebate and discount tiersInventory by item and days on hand
Check how long stock sits against confirmed orders, and stop building stock unsold.
Proven at Hikma Pharmaceuticals

Source: Hikma Pharmaceuticals PLC, Annual Report 2025, Strategic report.

Before buying stock ahead for a rebate, check the saving beats the cost of tying up cash.
Proven at Option Care Health

Source: Option Care Health, Inc., Form 10-K for fiscal year 2025 (filed 24 February 2026).

Check each customer's overdue balance before a new order ships, and report monthly what shipped to late payers.
Proven at Jamjoom Pharmaceuticals Factory

Source: Jamjoom Pharmaceuticals Factory Company, Q2 2026 Earnings Call Transcript.

03

Sales and demand

New product share targeted, closing pharmacies' patients welcomed and tracked.

ReadsSales by product and marketProduct launch datesDispensing records by patientBranch catchment map
Measure what share of revenue comes from products and contracts added in the last 3 years, and set a target.
Proven at Hikma Pharmaceuticals

Source: Hikma Pharmaceuticals PLC, Annual Report 2025, Strategic report.

When a nearby pharmacy closes, offer to take over its repeat prescriptions, and track how many patients stay.
Proven at CVS Health

Source: CVS Health Corporation, Form 10-K for fiscal year ended 31 December 2025.

Measure how much profit runs through government buyers who could switch to one appointed distributor, and plan that year now.
Proven at Pure Health

Source: Pure Health Holding PJSC, Integrated Annual Report 2025.

The money at stake.

Public figures, each with its company and year. An estimate is marked.

USD 4.3 billion

A US drug wholesaler's opioid litigation bill at end September 2025, payable over 13 years.

Proven at Cencora

Source: Cencora, Inc., Form 10-K for the fiscal year ended 30 September 2025. Cencora's accrued opioid litigation liability was USD 4.3 billion at 30 September 2025 (4.9 billion a year earlier), payable over 13 years, with about USD 416 million due within the following year.

USD 2.4 billion

A US drug distributor's operating cash flow in fiscal 2025, after a lost contract's working capital unwound.

Proven at Cardinal Health

Source: Cardinal Health, Inc., Form 10-K for the fiscal year ended 30 June 2026. Cardinal Health's fiscal 2025 operating cash flow of USD 2.4 billion absorbed the unwinding of negative net working capital tied to the expired OptumRx contracts and USD 798 million of opioid payments.

Grip at work

What your Grip looks like.

A sample company, in AED. Yours is built from your own files.

Ask Grip a question in a sentence, answered from the record. Sample figures.

What we stand on
01Money first

Every project shows the revenue, cost or cash it is worth, in your currency, from your own files, before you agree to it.

02Every project has proof

Every project runs on a client's Grip, was designed on our own Grip, or comes from a play a named company published, with the document we read it in.

03Your systems as they are

We read the systems you already use. Nothing to move, replace or clean up first.

04Value and money found in 2 weeks

A two-week pilot on one department, your first project live and its money delivered by Day 30, then one fixed monthly fee.

Questions

What pharma and medical distribution companies ask first.

Three answers, each with one public figure, its company and its document.

Question 1How can AI reduce rebates that cost more than they save in pharma and medical distribution?

AI reads prescriptions, supplier terms and stock records, branch by branch, and names the margin lost to price and timing and the cash held in stock, in AED. For scale: USD 64.9 million, fall in one US infusion pharmacy group's operating cash in 2025, mainly from stock bought early for supplier rebates (Option Care Health).

USD 64.9 millionFall in one US infusion pharmacy group's operating cash in 2025, mainly from stock bought early for supplier rebates.
Proven at Option Care Health

Source: Option Care Health, Inc., Form 10-K for fiscal year 2025 (filed 24 February 2026). Option Care Health's operating cash flow fell to $258,447 thousand in 2025 from $323,392 thousand, mainly because it built inventory through strategic purchases to maximise volume rebates and prompt-pay discounts and because receivables grew with revenue; buying for the rebate shows up as cost savings in margin but as cash tied up on the shelf.

Question 2What does an AI transformation programme in pharma and medical distribution start with?

It starts with the revenue, cost and cash you are losing today, read from the systems you already use. One workflow goes first, usually price and margin, read from sales by product with price and volume and price list and tender history. For scale: USD 4.3 billion, A US drug wholesaler's opioid litigation bill at end September 2025, payable over 13 years (Cencora).

USD 4.3 billionA US drug wholesaler's opioid litigation bill at end September 2025, payable over 13 years.
Proven at Cencora

Source: Cencora, Inc., Form 10-K for the fiscal year ended 30 September 2025. Cencora's accrued opioid litigation liability was USD 4.3 billion at 30 September 2025 (4.9 billion a year earlier), payable over 13 years, with about USD 416 million due within the following year.

Question 3How fast do pharma and medical distribution companies see results from AI?

A two-week pilot on one department finds the value and money in your own data before you commit. Your first project goes live, and its money is delivered, by Day 30.

The Perspace symbol resting on the water at blue hour

Start with one workflow.

Tell us what you want to fix. In a two-week pilot we find the value and money before you commit.

Discuss your business →See how we work →